Merck & Co Newsroom

Is Merck & Co., Inc. (MRK) the Best Weight Loss Stock to Buy Now According to Hedge Funds?

Yahoo Finance8minutes ago

Merck Gets FDA Review of Clesrovimab RSV Vaccine Candidate

WSJ16minutes ago

Express News | Merck & Co Inc - if Approved, Anticipates Clesrovimab Available for Ordering by July 2025

Reuters41minutes ago

Express News | Merck Announces FDA Acceptance of Biologics License Application for Clesrovimab, an Investigational Long-Acting Monoclonal Antibody Designed to Protect Infants From Rsv Disease During Their First Rsv Season

Reuters42minutes ago

Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110

Moomoo News20:32 ET · Ratings

Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123

Moomoo News20:32 ET · Ratings

Bernstein Keeps Their Hold Rating on Merck & Company (MRK)

TipRanks19:59 ET · Ratings

Merck Decides To End Favezelimab Clinical Development Program, And Stop Enrollment In Phase 3 KEYFORM-008 Trial

Benzinga16:33 ET

Express News | Merck & Co Inc - Patients in Keyform-008 Trial May Continue Therapy Until Study Completion

Reuters16:30 ET

Express News | Merck & Co Inc - Discontinues Clinical Development Programs for Vibostolimab and Favezelimab

Reuters16:30 ET

Express News | Merck Provides Update on Keyvibe and Keyform Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations With Pembrolizumab

Reuters16:30 ET

Another Week, Another Index Record | Lkive Stock

Kevin TraversDec 16 10:42 ET

Dow's 115-Point Rally Highlighted By Gains In Honeywell, Nike Shares

MarketWatchDec 16 10:08 ET

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Zacks Dec 16 10:05 ET

Merck's KEYTRUDA Approved in Combination With Chemotherapy in China to Treat Lung Cancer

MT NewswiresDec 16 07:14 ET

Express News | Merck’s Keytruda® (Pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, Iiia or Iiib Nsclc

ReutersDec 16 06:45 ET

Weekly Buzz: Tech stocks hit high scores on ominous day

Kevin TraversDec 13 16:29 ET

Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump

MT NewswiresDec 13 13:53 ET

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

BenzingaDec 13 12:15 ET

Market Mixed on Friday the 13th | Livestock

Kevin TraversDec 13 10:46 ET